基础医学与临床 ›› 2022, Vol. 42 ›› Issue (4): 651-655.doi: 10.16352/j.issn.1001-6325.2022.04.019

• 短篇综述 • 上一篇    下一篇

溶瘤病毒联合PD-1/PD-L1抑制剂的研究进展

甘兹颖1, 唐慧2*   

  1. 1.昆明理工大学 医学院; 2.昆明理工大学附属医院 云南省消化内镜临床医学中心昆明市肿瘤分子与免疫防治重点实验室, 云南 昆明 650032
  • 收稿日期:2020-12-14 修回日期:2021-04-06 出版日期:2022-04-05 发布日期:2022-04-01
  • 通讯作者: * htang1122@aliyun.com
  • 基金资助:
    国家自然科学基金(81460463);云南省科技厅-昆明医科大学联合基金[2019FE001(-173)],云南省消化内镜临床医学中心基金(2X2019-01-02);昆明市肿瘤分子与免疫重点实验室基金(2018-1-A-17334)

Research progress of oncolytic virus combined with PD-1/PD-L1 inhibitors

GAN Zi-ying1, TANG Hui2*   

  1. 1. School of Medical, Kunming University of Science and Technology; 2. Yunnan Digestive Endoscopy Clinical Medical Center, Kunming Key Laboratory of Tumor Molecular & Immune Prevention, the Affiliated Hospital of Kunming University of Science and Technology, Kunming 650032,China
  • Received:2020-12-14 Revised:2021-04-06 Online:2022-04-05 Published:2022-04-01
  • Contact: * htang1122@aliyun.com

摘要: 溶瘤病毒常以两种方式与程序性死亡受体1/程序性死亡受体-配体1(PD-1/PD-L1)为代表的免疫检查点抑制剂联合使用,一种为PD-1/PD-L1抑制剂联合基因重组修饰以及天然弱毒性的溶瘤病毒,另一种则是携带PD-1/PD-L1抗体基因的基因重组溶瘤病毒。

关键词: PD-1/PD-L1, 免疫检查点抑制剂, 溶瘤疗法

Abstract: Oncolytic viruses are often used in combination with immune checkpoint inhibitors represented in two ways by programmed cell death 1/programmed cell death-Ligand 1 (PD-1/PD-L1). One is oncolytic virus combined with PD-1/PD-L1 inhibitors, which is modified by gene recombination and natural weak toxicity, and another one is oncolytic virus with gene recombination carrying PD-1/PD-L1 antibody gene.

Key words: PD-1/PD-L1, immune checkpoint inhibitor, oncolytic therapy

中图分类号: